Targeting specific immune cells to improve immunosuppression treatments
Official title: Albumin-Amended Antibody Drug Conjugate (A3DC) for Immunosuppression
Funded at University of Utah · NIH-11119337 · Data updated 2026-11-12
This study is exploring a new way to help people with autoimmune diseases or those who have had organ transplants by using special treatments that can safely reduce certain immune cells, making it easier to manage their condition without causing long-term problems with their immune system.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $77,000 |
| NIH project number | 1R03EB037114-01 |
| Project ID | NIH-11119337 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals undergoing treatment for autoimmune diseases or those requiring organ transplants.
✕Less likely to help
Patients who do not have PD-1+ cell involvement in their condition may not benefit from this research.
What this research studies
This research focuses on developing a new approach to immunosuppression by targeting programmed death-1-positive (PD-1+) cells, which are crucial for maintaining immune responses in conditions like autoimmune diseases and organ transplants. The study aims to create antibody-drug conjugates that can effectively deplete these PD-1+ cells while preserving other immune cells, thus avoiding long-term immune deficiency. By engineering these targeted agents, the research seeks to enhance the effectiveness of immunosuppression without the adverse effects of current treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunosuppression therapies that minimize side effects and improve patient outcomes.
How similar studies have gone: While similar approaches have shown promise in targeting immune cells, this specific method of using antibody-drug conjugates for PD-1+ cell depletion is relatively novel.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Chen, Mingnan — University of Utah
- Study coordinator: Chen, Mingnan
Related research
Other NIH-funded projects on the same topics.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
AHR-driven immunosuppression in glioblastoma and new therapeutic targets
A personalized cancer study aims to understand why glioblastoma suppresses the immune system and to find ways to boost anti-tumor immunity in patients with this brain tumor.
-
Fibroblast-made GABA fuels PDAC immune suppression
In people with pancreatic cancer, this study explores how a specific cell type in the tumor environment uses a brain-like chemical (GABA) to dampen immune attack against the cancer.
-
Biomarker-guided reduction of immunosuppression after liver transplant
A multicenter trial tests whether using blood biomarkers to guide tapering of immunosuppression in adults with liver transplants can keep people healthy while lowering drug exposure.
-
Understanding and Overcoming T cell Immunosuppression in Glioblastoma (GBM)
A large research program is looking at how glioblastoma tumors weaken immune responses and how to boost immune cells to fight GBM.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.